Miconazole was compared with amphotericin B in the treatment of murine cryptococcosis. Both subcutaneous and intraperitoneal administration of miconazole produced serum levels higher than the minimum inhibitory concentration for the challenge strain. However, maximal tolerable doses of miconazole gave no increase in survival. When combined with amphotericin B, miconazole demonstrated neither additive nor antagonistic effects on survival. Spleen and brain counts of cryptococci were not lowered by miconazole; also, miconazole did not alter the effect of amphotericin B on reducing tissue counts. In vitro studies confirmed that the strain of Cryptococcus neoformans was quite susceptible to both miconazole and amphotericin B. However, miconazole had a delayed onset of antifungal activity. This was apparent even at miconazole levels 20 times greater than the minimum inhibitory concentration. Also, the antifungal activity of miconazole was markedly inhibited by serum. Delayed antifungal activity and serum inhibition may limit the in vivo effectiveness of miconazole in murine cryptococcosis.
Miconazole was compared with amphotericin B in the treatment of murine cryptococcosis. Both subcutaneous and intraperitoneal administration of miconazole produced serum levels higher than the minimum inhibitory concentration for the challenge strain. However, maximal tolerable doses of miconazole gave no increase in survival. When combined with amphotericin B, miconazole demonstrated neither additive nor antagonistic effects on survival. Spleen and brain counts of cryptococci were not lowered by miconazole; also, miconazole did not alter the effect of amphotericin B on reducing tissue counts. In vitro studies confirmed that the strain of Cryptococcus neoformans was quite susceptible to both miconazole and amphotericin B. However, miconazole had a delayed onset of antifungal activity. This was apparent even at miconazole levels 20 times greater than the minimum inhibitory concentration. Also, the antifungal activity of miconazole was markedly inhibited by serum. Delayed antifungal activity and serum inhibition may limit the in vivo effectiveness of miconazole in murine cryptococcosis.
Before the introduction of amphotericin B, cryptococcal meningitis was thought to be 100% fatal, although the course often ran a protracted period (2) . At present, amphotericin B remains the mainstay of antifungal chemotherapy. Although many patients have dramatically responded, the treatment is long, arduous, and complicated by both outright failures and late relapses after apparent responses (1, 2) . More recently the antimetabolite 5-fluorocytosine has been added in an effort to reduce the total dose (and toxicity) of amphotericin B (10) . Although this has been largely achieved, 5-fluorocytosine has brought its own forms of gastrointestinal and hematological toxicity and therefore is not totally benign. Furthermore, there are still patients who resist combined therapy with amphotericin B and 5-fluorocytosine.
A few of this last group of patients have been treated with miconazole, a newly introduced member of the imidazole family of drugs. Miconazole has been used with great success in treating murine coccidioidomycosis. On the basis of these studies, miconazole was given to patients with a variety of fungal infections, including a few with cryptococcosis (7, 8 In vitro studies. Amphotericin B susceptibility of cryptococci was determined in the Littman modification of Sabouraud broth, using serial tube dilutions. The sensitivity was 0.098 pg/ml. Miconazole susceptibility was determined by a previously described method and was 0.65,ug/ml (5) . Serum 
RESULTS
Preliminary studies with subcutaneous miconazole at 225 mg/kg twice daily produced a 60% mortality within 3 days. The same dose given i.p. produced a 10% mortality. This was due to miconazole itself and not to the polyethoxylated castor oil vehicle. At 125 mg/kg subcutaneously twice daily, mortality was approximately 10% from miconazole alone, and at 100 mg/kg twice daily, no mice died from miconazole. Serum levels of miconazole after various doses are shown in Table 1 . These indicate that miconazole achieved the minimum fungicidal levels of our strain of C. neoformans 1 h after a 100-mg/kg dose, but fell below that level within 4 h. Because of these relatively low levels, other groups of mice were treated with either 100 or 200 mg of miconazole per kg i.p. twice daily. This was given to provide maximal drug levels at the challenge site. The other antifungal agent, amphotericin B, was not lethal to mice in i.p. doses of up to 6 mg/kg per day for a 9-day course of treatment and subsequent 50-day observation period. Blood levels of amphotericin B were not measured.
The initial survival studies are shown in Fig.  1 . Ten mice per group received 125 mg of miconazole per kg subcutaneously or no drug. The first study (schedule 1) was conducted with an extremely high challenge of 108 CFU, and others (schedules 2 and 3) were conducted with a more modest challenge of 106 CFU. The latter dose was chosen because deaths from cryptococcosis did not begin until the week after treatment was discontinued. This permitted some distinction of toxicity deaths from cryptococcosis deaths. In all three studies, even when miconazole was begun a day before challenge, miconazoletreated mice did not survive longer than did controls. When spleen and brain counts were done on miconazole-treated and untreated controls, no differences were found (Table 2) . Therefore, miconazole itself appeared to have no benefit in the dose of 125 mg/kg twice a day. the site of cryptococcal challenge, there was no demonstrable benefit from adding miconazole.
Further studies were then conducted on the in vitro effects ofamphotericin B and miconazole on C. neoformans. As shown in Fig. 4 , amphotericin B at 0.1 ug/ml was rapidly fungicidal, with 95% killed in less than 4 h. However, at 0.01 pug/ml, amphotericin B had no effect, and cryptococci grew at the same rate as did the control. Miconazole at 5 and 0.5 ug/ml was also fungicidal, but the effect was delayed. There was no apparent decrease in cryptococcal colony counts for at least 8 h after exposure to the drug. Thereafter, CFU declined gradually but steadily. Miconazole at 0.1 ug/ml did not inhibit the growth of C. neoformans (data not shown). The same patterns occurred at 103, 104, and 105 CFU per ml of inoculum, so the delayed and gradual "kill" from miconazole did not appear to be inoculum dependent. Figure 4 also shows that combinations of miconazole and amphotericin B showed no synergism or antagonism at the doses studied. When miconazole was added to large concentrations of amphotericin B, there was no delayed fungal killing by amphotericin B, and when miconazole was added to snall concentrations of amphotericin B, there was no acceleration in the speed of miconazole killing.
The effects of both amphotericin B and miconazole were rather serum dependent (Fig. 5) . This was possibly due to protein binding, which occurs with both drugs. At pH 5.6, cryptococci grew as well or better in mouse serum than in Sabouraud broth. However, although both amphotericin B and miconazole were able to kill cryptococci in Sabouraud broth, much higher levels were required in serum. The inhibitory effect of miconazole was as gradual in serum as it was in Sabouraud broth, indicating that this effect was not dependent on the culture medium.
At pH 7.4, cryptococci grew as rapidly in Sabouraud broth as they did at pH 5.6 . However, at pH 7.4, serum inhibited the growth of cryptococci. By 30 h of incubation, cryptococcal counts had fallen to between 50 and 10% of the initial inoculum size. The pH dependence of the serum inhibitory activity suggested to us that transferrin might be involved. Free iron is important for growth of Candida albicans in serum and has also been suggested for C. neoformans. At pH 7.4, transferrin removes free iron, making it unavailable, whereas at a pH of less than 6 transferrin is unable to bind iron and it is available (3, 9) . We tested the possible importance of transferrin by comparing growth in serum with and without added iron. In serum to which iron was added, growth was as rapid pg/ml plus amphotericin B, 0.01 pug/ml; and (F) miconazole, 0.5 pg/ml plus amphotericin B, 0.1 pg/ml. at pH 7.4 as it was at pH 5.6. Miconazole inhibition by serum was not affected by the addition of iron; results with added iron were quite similar to those shown in Fig. 5 . In addition to mouse serum, several studies were conducted using pooled human serum from healthy AB+ donors and from a healthy subject working in this laboratory. Kinetics of growth in human serum and miconazole inhibition by human serum were similar to those in mouse serum.
In a final study, miconazole or amphotericin B was given i.p. to groups of five mice. At 2 h after drug administration, the mice were exsanguinated and growth curves of C. neofornans were perfonned in 100% mouse serum at pH 5.6 (Fig. 6) . Amphotericin B at 6.25 mg/kg was rapidly fungicidal. On the other hand, only the 200-mg/kg miconazole dose produced inhibitory activity in the serum, and this was less than 1
Growth of C. neoformans in either Sabouraud broth or 100% mouse serum, pH 5.6, after an inoculum of 10' CFU/ml and incubation at 37°C. The vertical axis indicates growth or killing of cryptococci on a logarithmic scale. For low-drug-concentration study, A -control serum; B -amphotericin B, 0.1 pg/ml, serum; C = miconazole, 0.5 pig/ml, serum; D -amphotericin B, 0.1 pg/ml, plus miconazole, 0.5 pg/ml, serum; E = control, Sabouraud broth; F -amphotericin B, 0.1 pg/mi, Sabouraud broth; G -miconazole, 0.5 pg/ml, Sabouraud broth; and H = amphotericin B, 0.1 pg/mi, plus miconazole, 0.5 pg/mi, Sabouraud broth. For high-drug-concentration study, A -control serum; B -amphotericin B, 0.1 pg/ml, serum; C = amphotericin B, 2.0 pg/mi, serum; D -miconazole, 10 pg/ml, serum; E -control, Sabouraud broth; and F = miconazole, 10 pg/ml, Sabouraud broth. log decrease. A portion of the same serum had 5.6 ug of miconazole per ml, an extremely high level (Table 3 ). This poor serum fungicidal activity correlated with the failure of even this large dose to prolong survival, as previously shown in Fig. 3 . DISCUSSION Miconazole has been dramatically effective in vitro against a number of fungi. Studies were extended in vivo to murine coccidioidomycosis, where the drug proved to be an excellent thera- Another likely candidate for miconazole therapy would be C. neoformans. This is because (i) patients may be refractory to conventional therapy, and (ii) several strains of C. neoformans including our own appear to be susceptible in vitro to miconazole. However, we could not confirm that miconazole is of protective value in mice challenged with this strain of C. neoformans. Furthermore, although amphotericin B is clearly protective against cryptococcosis, we could not demonstrate any additive (or antagonistic) effect of miconazole on amphotericin B therapy in murine cryptococcosis.
There could be several reasons for this discrepancy between in vitro susceptibility and in vivo resistance. First, because miconazole is known to penetrate poorly into human cerebrospinal fluid, it was possible that miconazole might sterilize the peritoneal site of inoculation but not a remote protected site such as the central nervous system. We found no support for this because the spleen counts of cryptococci were not significantly different between miconazole-treated mice and nontreated controls. Also, amphotericin B (which penetrates the cerebrospinal fluid in minimal amounts) dramatically lowered cryptococcal counts in both spleen and brain in treated mice. Very low doses of i.p. amphotericin B protected mice, whereas very high doses of i.p. miconazole failed.
As a second possibility, the miconazole might have held the cryptococci in check as a static agent only to have the fungi grow unchecked after the drug was stopped. If this were the case, one would still expect at least a modest delay in mortality from miconazole and a reduction in spleen counts compared with controls (mice were sacrificed at 1 day after the treatment was stopped). Neither occurred.
A third possible explanation of the failure of miconazole is that we selected an unsuitable animal model for the demonstration of miconazole activity. There are three arguments against this. The first is that BALB/c mice have been used successfully in studies of protective ixnmunization against cryptococcosis in this laboratory (Graybill and Taylor, in press). The second is that another chemotherapeutic agent, amphotericin B, was quite satisfactory in the present studies. The third is the success of miconazole in murine coccidioidomycosis.
A fourth possibility would be that the strain of cryptococcus selected was "inappropriate" and did not reflect a "majority" of cryptococci that are susceptible to miconazole in vitro and in vivo. Although this has not been excluded, it still does not explain the discrepancy between in vitro susceptibility and in vivo resistance seen with this strain. It is also not likely that the challenge dose was the critical factor, because the effect was apparent at doses that were quite satisfactory in showing protection in concurrent mice treated with amphotericin B.
Fifth, one may argue that not enough micon- 7 days postchallenge (unpublished data in our laboratory). Treatment was thus begun when there were few intracerebral cryptococci. Finally, the daily doses used were equivalent to those found protective against murine coccidioidomycosis. Thus, although we cannot absolutely exclude "inadequate" dose, we used maximal miconazole within the limits of toxicity, with no benefit. Furthermore, even if miconazole had limited value by itself, it might be anticipated to have some effect on mice concurrently treated with amphotericin B. Over a broad dose range of amphotericin B, we could find no benefit of added miconazole therapy. It should be added that we also did not find antagonism either in vivo or in vitro. This may also be important, in view of recent observations that patients on miconazole plus amphotericin B therapy appear to have lower serum antifumgal activity than do those on amphotericin B alone (6). Our observations do not directly refute these studies as the experimental methods were not closely comparable.
Finally, it is possible that the kinetics of miconazole activity might be biologically important. The effects of amphotericin B on membrane permeability of fungi are apparent within moments of exposure to the drug, well before any killing occurs (4) . When the relatively crude test of colony counts was used, miconazole exerted no apparent effect for up to 6+ h of exposure to the drug. It is possible that prolonged contact at pharmacological levels must be achieved for any killing to occur. In addition to this delayed and "slow" antifungal activity of miconazole, the drug is much less effective in the presence of serum. This was demonstrated with in vitro studies in human serum as well as mouse serum. If prolonged in vivo contact of miconazole and cryptococci is required at levels exceeding the minimum inhibitory concentration and if serum inhibition is important in vivo, it is reasonable that these two effects could negate even larger doses of miconazole than those we used.
In any case, the dramatic effects of miconazole in murine coccidioidomycosis could not be reproduced with a mouse model of cryptococcosis. There is very little experience with miconazole in human cryptococcosis. Although both responses and failures have been reported, it is too early to determine whether these studies will have predictive value on the ultimate status of miconazole in human cryptococcosis.
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